Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,557.60GBp
19 Oct 2018
Change (% chg)

47.00 (+3.11%)
Prev Close
1,510.60
Open
1,523.20
Day's High
1,558.40
Day's Low
1,516.00
Volume
10,927,275
Avg. Vol
7,734,252
52-wk High
1,634.48
52-wk Low
1,235.20

Chart for

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 1.14
Market Cap(Mil.): £73,963.92
Shares Outstanding(Mil.): 4,960.48
Dividend: 19.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 26.83 29.75 32.14
EPS (TTM): 0.55 -- --
ROI: 10.14 13.18 12.83
ROE: 121.78 15.14 14.95

Stada, buyout funds in race for Bristol-Myers' French business: sources

LONDON German generic drugmaker Stada is vying with a group of European buyout funds for control of Bristol-Myers Squibb's French over-the-counter drugs business, sources familiar with the matter told Reuters.

Oct 08 2018

UPDATE 1-Stada, buyout funds in race for Bristol-Myers' French business - sources

LONDON, Oct 8 German generic drugmaker Stada is vying with a group of European buyout funds for control of Bristol-Myers Squibb's French over-the-counter drugs business, sources familiar with the matter told Reuters.

Oct 08 2018

Stada, buyout funds in race for Bristol-Myers' French business - sources

LONDON, Oct 8 German generic drugmaker Stada is vying with a group of European buyout funds for control of Bristol-Myers Squibb's French over-the-counter drugs business, sources familiar with the matter told Reuters.

Oct 08 2018

BRIEF-Boston Pharmaceuticals says licenses five programmes from GSK

* BOSTON PHARMACEUTICALS SAYS HAS IN-LICENSED A PORTFOLIO OF FIVE EARLY DEVELOPMENT PROGRAMMES FROM GLAXOSMITHKLINE

Oct 03 2018

GSK resumes some doctor payments, backtracking on blanket ban

LONDON GlaxoSmithKline, which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances.

Oct 02 2018

GSK resumes some doctor payments, backtracking on blanket ban

LONDON, Oct 2 GlaxoSmithKline, which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances.

Oct 02 2018

New UK Serious Fraud Office head launches recruitment drive

LONDON, Sept 27 Lisa Osofsky, the new head of the UK Serious Fraud Office (SFO), has launched her first organisational overhaul since taking the helm of the country's top white collar crime prosecutor with a recruitment drive for two senior specialists.

Sep 27 2018

Nestle aims to shed skin unit to focus on food, nutrition

LONDON/ZURICH Nestle put its skin health unit up for sale on Thursday, as the maker of Nescafe and Perrier water ditches underperforming businesses and fends off criticism from an activist investor demanding an overhaul.

Sep 20 2018

UPDATE 3-Nestle aims to shed skin unit to focus on food, nutrition

* Hedge fund Third Point demanding bolder corporate moves (Changes headline, adds context, comments)

Sep 20 2018

PRESS DIGEST- Financial Times - Sept 19

Sept 19 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Sep 18 2018

Earnings vs. Estimates